Corilagin alleviates atherosclerosis by inhibiting NLRP3 inflammasome activation via the Olfr2 signaling pathway in vitro and in vivo

Simple item page
dc.contributor.authorMao, Jinqian
dc.contributor.authorFisher, David
dc.date.accessioned2025-10-29T10:57:49Z
dc.date.available2025-10-29T10:57:49Z
dc.date.issued2024
dc.description.abstractIntroduction: Atherosclerosis, a leading cause of global cardiovascular mortality, is characterized by chronic inflammation. Central to this process is the NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome, which significantly influences atherosclerotic progression. Recent research has identified that the olfactory receptor 2 (Olfr2) in vascular macrophages is instrumental in driving atherosclerosis through NLRP3- dependent IL-1 production. Methods: To investigate the effects of corilagin, noted for its anti-inflammatory attributes, on atherosclerotic development and the Olfr2 signaling pathway, our study employed an atherosclerosis model in ApoE−/− mice, fed a high-fat, high-cholesterol diet, alongside cellular models in Ana-1 cells and mouse bone marrow-derived macrophages, stimulated with lipopolysaccharides and oxidized low-density lipoprotein. Results: The vivo and vitro experiments indicated that corilagin could effectively reduce serum lipid levels, alleviate aortic pathological changes, and decrease intimal lipid deposition. Additionally, as results showed, corilagin was able to cut down expressions of molecules associated with the Olfr2 signaling pathway. Discussion: Our findings indicated that corilagin effectively inhibited NLRP3 inflammasome activation, consequently diminishing inflammation, macrophage polarization, and pyroptosis in the mouse aorta and cellular models via the Olfr2 pathway. This suggests a novel therapeutic mechanism of corilagin in the treatment of atherosclerosis.
dc.identifier.citationMao, J., Chen, Y., Zong, Q., Liu, C., Xie, J., Wang, Y., Fisher, D., Hien, N.T.T., Pronyuk, K., Musabaev, E. and Li, Y., 2024. Corilagin alleviates atherosclerosis by inhibiting NLRP3 inflammasome activation via the Olfr2 signaling pathway in vitro and in vivo. Frontiers in Immunology, 15, p.1364161.
dc.identifier.urihttps://doi.org/10.3389/fimmu.2024.1364161
dc.identifier.urihttps://hdl.handle.net/10566/21290
dc.language.isoen
dc.publisherFrontiers Media SA
dc.subjectAtherosclerosis
dc.subjectCorilagin
dc.subjectInflammation
dc.subjectNLRP3 inflammasome
dc.subjectOlfr2
dc.titleCorilagin alleviates atherosclerosis by inhibiting NLRP3 inflammasome activation via the Olfr2 signaling pathway in vitro and in vivo
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
mao_corilagin_alleviates_atherosclerosis_by_inhibiting_2024.pdf
Size:
13.77 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Articles (Medical Bioscience)